Telix Pharmaceuticals Secures Key Reimbursement Status for Gozellix

An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.

Telix Pharmaceuticals announced that the U.S. Centers for Medicare & Medicaid Services has granted Transitional Pass-Through payment status for Gozellix, their next-generation PSMA-PET imaging agent for prostate cancer. This designation allows for separate reimbursement under the Hospital Outpatient Prospective Payment System, effective October 1, 2025, and is a key milestone in Telix’s U.S. commercial strategy. Gozellix offers a longer shelf life and extended distribution radius, improving access and efficiency in prostate cancer imaging. The reimbursement status is expected to reduce patient costs and enhance access to advanced imaging, strengthening Telix’s market position as a leader in PSMA-PET/CT imaging.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, United Kingdom, Brazil, Canada, Europe, and Japan. The company focuses on addressing significant unmet medical needs in oncology and rare diseases, with a portfolio of clinical and commercial stage products. Telix is publicly traded on the Australian Securities Exchange and the Nasdaq Global Select Market.

Average Trading Volume: 2,611,753

Technical Sentiment Signal: Sell

Current Market Cap: A$4.92B

For an in-depth examination of TLX stock, go to TipRanks’ Overview page.